NICE rejects Pfizer’s rare heart disease treatment Vyndaqel
The final guidance publication comes following an appeal against earlier draft recommendations
Read More
Tag: ATTR-CM
Vyndaqel first treatment approved in Europe for ATTR-CM
The decision was based on results from the Phase III ATTR-ACT study.
Read More
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
